| Name | Title | Contact Details |
|---|
Walgreens Boots Alliance (Nasdaq: WBA) is the first global pharmacy-led, health and wellbeing enterprise. The company`s heritage of trusted health care services through community pharmacy care and pharmaceutical wholesaling dates back more than 100 years. Walgreens Boots Alliance is the largest retail pharmacy, health and daily living destination across the U.S. and Europe. Walgreens Boots Alliance and the companies in which it has equity method investments together have a presence in more than 25* countries and employ more than 385,000* people. The company is a global leader in pharmacy-led, health and wellbeing retail and, together with the companies in which it has equity method investments, has approximately 14,500** stores in 11* countries as well as one of the largest global pharmaceutical wholesale and distribution networks, with more than 390* distribution centers delivering to more than 230,000*** pharmacies, doctors, health centers and hospitals each year in more than 20* countries. In addition, Walgreens Boots Alliance is one of the world`s largest purchasers of prescription drugs and many other health and wellbeing products. The company`s portfolio of retail and business brands includes Walgreens, Duane Reade, Boots and Alliance Healthcare, as well as increasingly global health and beauty product brands, such as No7, Soap & Glory, Liz Earle, Sleek MakeUP and Botanics. More company information is available at www.walgreensbootsalliance.com. * As of 31 August 2017, using publicly available information for AmerisourceBergen. ** As of 28 June 2018. *** For 12 months ending 31 August 2017, using publicly available information for AmerisourceBergen.
ORIC was established in 2014 with a bold vision of Overcoming Resistance in Cancer. Resistance limits the efficacy of otherwise significant cancer treatment breakthroughs, regardless of modality. Our ambition at ORIC is to discover and develop innovative therapies that benefit patients with cancer, including by making existing therapies more effective for a longer period of time. Our initial project was a small molecule antagonist of the glucocorticoid receptor (GR), which has been implicated in resistance to various treatment modalities—including chemotherapy, immunotherapy, and anti-hormonal therapy—and across multiple cancers. The resulting product candidate, ORIC-101, is now being studied in clinical trials for a range of solid tumors. ORIC-101 and other pipeline programs are a result of rigorous, hands-on experimentation and medicinal chemistry efforts led by our internal team of scientists in biology, medicinal chemistry, DMPK and translational medicine, with assistance from academic collaborators and continued guidance from our founders and board members. This collective team maintains an unwavering focus on improving the lives of patients by tackling the problem of cancer treatment resistance.
We help you connect patients and researchers to ensure data reliability, with proven solutions that simplify every step of the patient journey. Our deep therapeutic area expertise, agile technology and service scale enable us to minimize risk, innovate, and support your important work. We seek speed, efficiency and reduced variability to help you extend the reach of drug development, expand patient opportunities and improve data quality helping you bring life-changing therapies to our families and communities around the world.
AustarPharma, LLC is a Edison, NJ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
GEORGE FISCHER SIGNET INC is a El Monte, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.